Sernova Biotherapeutics (TSX: SVA) has announced it will participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on October 1, 2026, alongside merger partner Seraxis Holdings. The joint presentation will focus on the companies' proposed combination to create BetaNova Biotherapeutics, a clinical-stage entity targeting type 1 diabetes cell replacement. The event offers investors a direct look at the strategic rationale behind a merger agreement announced on September 8, 2026, with the transaction expected to close in November 2026, subject to regulatory and shareholder approvals.

Key Points

  • Sernova Biotherapeutics, Inc. (TSX: SVA | OTC: SEOVF | FSE/XETRA: PSHO)
  • Sernova and Seraxis will present jointly at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 1, 2026, at 1:30 p.m. Eastern Time
  • The proposed merger to form BetaNova Biotherapeutics is expected to close in November 2026, pending shareholder, court, TSX, and other customary approvals
  • Investors should watch for progress on merger approvals and any updates on BetaNova's combined T1D cell-replacement platform

Joint Leadership to Present BetaNova Merger Strategy at Virtual Conference

Jonathan Rigby, President and CEO of Sernova, will present alongside Will Rust, Ph.D., President and CEO of Seraxis, in a fireside-style format that includes an interactive Q&A open to conference attendees. The October 1 session will address the strategic and scientific rationale for the proposed merger and outline plans for the combined company. Qualified investors may also request one-on-one meetings with management through Noble Capital Markets. A replay of the presentation will be available for 90 days following the event on Sernova's website and through Noble Capital Markets' Channelchek investor platform.

Complementary Technologies Driving the Proposed BetaNova Platform

The proposed combination is designed to integrate Seraxis' stem cell-derived pancreatic islet programs — SR-02, which is IND-cleared, and SR-03 — along with its in-house cGMP manufacturing capabilities, with Sernova's clinically validated Cell Pouch Bio-hybrid Organ™. The release states this integrated approach is intended to span therapeutic cells, scalable manufacturing, and cell delivery within a single platform. The combined entity, BetaNova Biotherapeutics, would be domiciled in the United States and focus exclusively on advancing islet cell-replacement therapies for type 1 diabetes patients.

Merger Timeline and Conditions Investors Should Monitor

Sernova and Seraxis announced their definitive merger agreement on September 8, 2026. The transaction is expected to close in November 2026, subject to shareholder, court, TSX, and other customary regulatory approvals and closing conditions. The proposed combined company, BetaNova Biotherapeutics, would operate as a clinical-stage regenerative medicine business. Investors may be watching whether all required approvals are obtained within the anticipated timeframe. The immediate share price impact was not clear from available public information.